Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature.

Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BT, Tjarks W, Barth RF, Claffey K, Backer JM.

Mol Cancer Ther. 2005 Sep;4(9):1423-9.

2.

Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2.

Backer MV, Budker VG, Backer JM.

J Control Release. 2001 Jul 6;74(1-3):349-55.

PMID:
11489517
3.

Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy.

Shukla S, Wu G, Chatterjee M, Yang W, Sekido M, Diop LA, Müller R, Sudimack JJ, Lee RJ, Barth RF, Tjarks W.

Bioconjug Chem. 2003 Jan-Feb;14(1):158-67.

PMID:
12526705
4.
5.

Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.

Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS.

Cancer Res. 2008 Jan 15;68(2):521-9. doi: 10.1158/0008-5472.CAN-07-3217.

6.

Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.

Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, Perret GY.

Life Sci. 2006 Nov 17;79(25):2370-81. Epub 2006 Aug 16.

PMID:
16959272
7.

Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT).

Thirumamagal BT, Zhao XB, Bandyopadhyaya AK, Naranyanasamy S, Johnsamuel J, Tiwari R, Golightly DW, Patel V, Jehning BT, Backer MV, Barth RF, Lee RJ, Backer JM, Tjarks W.

Bioconjug Chem. 2006 Sep-Oct;17(5):1141-50.

PMID:
16984121
8.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

9.

Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.

Chung TW, Kim SJ, Choi HJ, Kim KJ, Kim MJ, Kim SH, Lee HJ, Ko JH, Lee YC, Suzuki A, Kim CH.

Glycobiology. 2009 Mar;19(3):229-39. doi: 10.1093/glycob/cwn114. Epub 2008 Oct 30.

PMID:
18974200
10.

Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells.

Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS.

Cancer Res. 1999 Jan 1;59(1):183-8.

11.

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T.

Cancer Res. 2006 Sep 15;66(18):9134-42.

12.

Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.

Kimura Y, Sumiyoshi M, Baba K.

Cancer Sci. 2008 Oct;99(10):2083-96. doi: 10.1111/j.1349-7006.2008.00948.x.

13.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.

Cancer Res. 2009 Oct 15;69(20):8009-16. doi: 10.1158/0008-5472.CAN-08-4889. Epub 2009 Oct 6.

14.

Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.

Jung MH, Lee SH, Ahn EM, Lee YM.

Carcinogenesis. 2009 Apr;30(4):655-61. doi: 10.1093/carcin/bgp039. Epub 2009 Feb 18.

PMID:
19228635
15.
16.

Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.

Weigand M, Hantel P, Kreienberg R, Waltenberger J.

Angiogenesis. 2005;8(3):197-204. Epub 2005 Nov 19.

PMID:
16328160
17.

Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.

Schomber T, Zumsteg A, Strittmatter K, Crnic I, Antoniadis H, Littlewood-Evans A, Wood J, Christofori G.

Mol Cancer Ther. 2009 Jan;8(1):55-63. doi: 10.1158/1535-7163.MCT-08-0679.

18.

Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.

Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, Vogel H, Hou LC, Tse V, Rosenblum MG, Chen X.

J Nucl Med. 2007 Mar;48(3):445-54.

20.

Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth.

Purhonen S, Palm J, Rossi D, Kaskenpää N, Rajantie I, Ylä-Herttuala S, Alitalo K, Weissman IL, Salven P.

Proc Natl Acad Sci U S A. 2008 May 6;105(18):6620-5. doi: 10.1073/pnas.0710516105. Epub 2008 Apr 28.

Supplemental Content

Support Center